Sandoz wins Health Canada approval for generic semaglutide injection

Health Canada granted marketing authorization for Sandoz Semaglutide, a generic version of Novo Nordisk’s Ozempic. Approval covers once-weekly subcutaneous use in adults with type 2 diabetes to improve glycemic control. Product set to launch in three dose strengths via two pen presentations. Sandoz sees no material 2026 financial impact from any potential generic semaglutide launches. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2399568_en) on September 18, 2026, and is solely responsible for the information contained therein. (C)